ESR2 and pachyonychia congenita: Treatment with the ERβ agonist 8β-VE2 induces beneficial effects over current AR-targeting therapies by decreasing survival of CRPC cells and inhibiting the biological effects mediated by AR variants in the VCaP model of PC bone metastasis (50).